2026/05/04 by Daniel Vilser, I. Han, Katrin Vogel +14 · 1 voice · 1 citation
Medicine · Neuroscience · #Autoimmune and Inflammatory Disorders Research #Long-Term Effects of COVID-19 #Tryptophan and brain disorders
paper · pdf · doi:10.1038/s41467-026-72224-y
openalex publication_date 2026/05/04 · openalex created_date 2026/05/05 · openalex updated_date 2026/07/23
Abstract Most children and adolescents recover rapidly from SARS-CoV-2 infection, yet a subset develops paediatric long COVID (LC). How immune ontogeny shapes LC biology and heterogeneity remains unclear. We deeply phenotype a two-visit cohort with severe LC ( n = 74) and controls ( n = 27) spanning up to 3.2 years post index infection. Symptom burden remains high and neurofilament light chain (NfL) percentiles inversely associate with functional status (Bell score; r <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mi>r</mml:mi> </mml:math> = −0.3536, P = 0.0060). Cardiopulmonary assessment and serology are unremarkable. Conventional autoantibodies are not enriched, whereas anti-DFS70 supports subgrouping. Immune features are temporally structured; SARS-CoV-2–associated mediators decline within 1 year, while innate-weighted, Th2-skewed cytokines persist. Metabolomics (43 metabolites) recapitulate the identified subgroups and align with EBV serostatus, disease phase (<1 year versus years 1–3.2), and anti-DFS70 positivity. In EBV-naïve LC, higher haemoglobin concentration (MCHC) tracks worse function, whereas higher IL-12p40, thiamine and basophils track milder impairment (all P ≤ 0.0170). These data delineate immune-metabolic and haematological axes of paediatric LC heterogeneity and support biomarker-guided stratification.